{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:40:03Z","timestamp":1794264003043,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic thromboembolic pulmonary hypertension (CTEPH) is an uncommon complication of acute pulmonary embolism (PE), resulting in elevated pulmonary pressure and higher risk of PE recurrence. Therefore, lifelong anticoagulant therapy is mandatory in patients diagnosed with this condition. Despite anticoagulation with vitamin K antagonists (VKAs) has always represented the standard of care in this setting, the spread of direct oral anticoagulants (DOACs) raised the question of the potential applicability of their use also in CTEPH. We performed a systematic review and meta-analysis of randomized and observational studies focusing on patients with CTEPH treated with either VKAs or DOACs. Key clinical outcomes as venous thromboembolism (VTE) recurrence, bleedings (major bleeding, clinically relevant non-major bleeding, and intracranial hemorrhage), and mortality were evaluated. Overall, 12 studies including 4071 patients were selected in the quantitative analysis, 10 had an observational design. We found no difference between DOACs and VKAs for VTE recurrence (RR 0.99, 95% CI 0.40\u20132.43), overall bleedings (RR 0.77, 95% CI 0.45\u20131.32), and all-cause death (RR 0.58, 95% CI 0.30\u20131.14). These results were consistent for the aforementioned outcomes also in a sensitivity analysis pooling the results of RCTs and prospective studies only (OR 0.75, 95% CI 0.24\u20132.38; OR 0.59, 95% CI 0.22\u20131.56; OR 0.69, 95% CI 0.01\u201374.68; respectively). DOACs appear to be as effective and safe as VKAs for patients with CTEPH, therefore their use may be considered in the absence of clinical contraindications. Larger randomized controlled trials are warranted to further confirm our findings.<\/jats:p>","DOI":"10.1007\/s11739-025-04257-y","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:11:51Z","timestamp":1768925511000},"page":"971-978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anticoagulation in chronic thromboembolic pulmonary hypertension: an updated systematic review and meta-analysis"],"prefix":"10.1007","volume":"21","author":[{"given":"Filippo","family":"Catalani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9729-3214","authenticated-orcid":false,"given":"Emanuele","family":"Valeriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Campello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Pannunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Sgro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandor","family":"Gy\u00f6rik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"36","key":"4257_CR1","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1093\/eurheartj\/ehac206","volume":"43","author":"L Valerio","year":"2022","unstructured":"Valerio L, Mavromanoli A, Barco S (2022) Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J 43(36):3387\u20133398","journal-title":"Eur Heart J"},{"key":"4257_CR2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01792-2016","author":"YM Ende-Verhaar","year":"2017","unstructured":"Ende-Verhaar YM et al (2017) Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01792-2016","journal-title":"Eur Respir J"},{"issue":"2","key":"4257_CR3","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1183\/09031936.00049312","volume":"41","author":"IM Lang","year":"2013","unstructured":"Lang IM, Pesavento R, Bonderman D, Yuan JXJ (2013) Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 41(2):462\u2013468. https:\/\/doi.org\/10.1183\/09031936.00049312","journal-title":"Eur Respir J"},{"issue":"4","key":"4257_CR4","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1160\/TH16-10-0790","volume":"117","author":"ML Bochenek","year":"2017","unstructured":"Bochenek ML et al (2017) From thrombosis to fibrosis in chronic thromboembolic pulmonary hypertension. Thromb Haemost 117(4):769\u2013783. https:\/\/doi.org\/10.1160\/TH16-10-0790","journal-title":"Thromb Haemost"},{"key":"4257_CR5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022","author":"M Humbert","year":"2023","unstructured":"Humbert M et al (2023) 2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.00879-2022","journal-title":"Eur Respir J"},{"issue":"4","key":"4257_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2019","unstructured":"Konstantinides SV et al (2019) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J 41(4):543\u2013603. https:\/\/doi.org\/10.1093\/eurheartj\/ehz405","journal-title":"Eur Heart J"},{"issue":"8","key":"4257_CR7","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.jtha.2023.03.036","volume":"21","author":"K Hosokawa","year":"2023","unstructured":"Hosokawa K et al (2023) Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study. J Thromb Haemost 21(8):2151\u20132162. https:\/\/doi.org\/10.1016\/j.jtha.2023.03.036","journal-title":"J Thromb Haemost"},{"issue":"6","key":"4257_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.healun.2022.02.002","volume":"41","author":"M Humbert","year":"2022","unstructured":"Humbert M et al (2022) Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 41(6):716\u2013721. https:\/\/doi.org\/10.1016\/j.healun.2022.02.002","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"4257_CR9","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/jth.14649","volume":"18","author":"K Bunclark","year":"2020","unstructured":"Bunclark K et al (2020) A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 18(1):114\u2013122. https:\/\/doi.org\/10.1111\/jth.14649","journal-title":"J Thromb Haemost"},{"issue":"5","key":"4257_CR10","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1161\/CIRCULATIONAHA.123.067528","volume":"149","author":"K Hosokawa","year":"2024","unstructured":"Hosokawa K et al (2024) A multicenter, single-blind, randomized, warfarin-controlled trial of edoxaban in patients with chronic thromboembolic pulmonary hypertension: KABUKI trial. Circulation 149(5):406\u2013409. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067528","journal-title":"Circulation"},{"key":"4257_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","author":"D Moher","year":"2009","unstructured":"Moher D et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"issue":"6","key":"4257_CR12","first-page":"727","volume":"18","author":"GA Wells","year":"2014","unstructured":"Wells GA et al (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Appl Eng Agric 18(6):727\u2013734","journal-title":"Appl Eng Agric"},{"key":"4257_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"4257_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101232","author":"C Burmeister","year":"2023","unstructured":"Burmeister C et al (2023) Head-to-head comparison between direct oral anticoagulants and vitamin K antagonists for chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. Curr Probl Cardiol. https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101232","journal-title":"Curr Probl Cardiol"},{"key":"4257_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/10760296241257931","author":"T Zhang","year":"2024","unstructured":"Zhang T, Guo L, Liang S, Liu H (2024) Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension: first meta-analysis of prospective studies. Clin Appl Thromb Hemost. https:\/\/doi.org\/10.1177\/10760296241257931","journal-title":"Clin Appl Thromb Hemost"},{"key":"4257_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102377","author":"AM Salazar","year":"2024","unstructured":"Salazar AM, Panama G, Kim AG, Rayamajhi S, Abela GS (2024) Clinical outcomes between direct oral anticoagulants versus vitamin K antagonists in chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis. Curr Probl Cardiol. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102377","journal-title":"Curr Probl Cardiol"},{"issue":"36","key":"4257_CR17","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC et al (2024) 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 45(36):3314\u20133414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176","journal-title":"Eur Heart J"},{"issue":"1","key":"4257_CR18","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1161\/CIR.0000000000001193","volume":"149","author":"JA Joglar","year":"2024","unstructured":"Joglar JA et al (2024) 2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 149(1):E1\u2013E156. https:\/\/doi.org\/10.1161\/CIR.0000000000001193","journal-title":"Circulation"},{"issue":"19","key":"4257_CR19","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","volume":"4","author":"TL Ortel","year":"2020","unstructured":"Ortel TL et al (2020) American society of hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 4(19):4693\u20134738. https:\/\/doi.org\/10.1182\/bloodadvances.2020001830","journal-title":"Blood Adv"},{"issue":"9921","key":"4257_CR20","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955\u2013962. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"issue":"12","key":"4257_CR21","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04","volume":"124","author":"N Van Es","year":"2014","unstructured":"Van Es N, Coppens M, Schulman S, Middeldorp S, \u00a8Uller HRB (2014) Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 124(12):1968\u20131975. https:\/\/doi.org\/10.1182\/blood-2014-04","journal-title":"Blood"},{"key":"4257_CR22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01097-2017","author":"MND Di Minno","year":"2017","unstructured":"Di Minno MND et al (2017) Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.01097-2017","journal-title":"Eur Respir J"},{"issue":"2","key":"4257_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.repc.2021.09.023","volume":"42","author":"S Barati","year":"2023","unstructured":"Barati S et al (2023) Evaluating the efficacy and safety of rivaroxaban as a warfarin alternative in chronic thromboembolic pulmonary hypertension patients undergoing pulmonary endarterectomy: a randomized clinical trial. Rev Port Cardiol 42(2):139\u2013144. https:\/\/doi.org\/10.1016\/j.repc.2021.09.023","journal-title":"Rev Port Cardiol"},{"issue":"5","key":"4257_CR24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.healun.2023.12.005","volume":"43","author":"R Takano","year":"2024","unstructured":"Takano R et al (2024) Recurrent pulmonary hypertension after balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 43(5):737\u2013744. https:\/\/doi.org\/10.1016\/j.healun.2023.12.005","journal-title":"J Heart Lung Transplant"},{"issue":"41","key":"4257_CR25","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1183\/09031936.00039212","volume":"4","author":"I Henkens","year":"2013","unstructured":"Henkens I, Hazenoot T, Boonstra A, Huisman M, Vonk-Noordegraaf A (2013) Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J 4(41):872\u2013878","journal-title":"Eur Respir J"},{"key":"4257_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74481-7","author":"Y Nakano","year":"2024","unstructured":"Nakano Y et al (2024) Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-024-74481-7","journal-title":"Sci Rep"},{"key":"4257_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019873545","author":"S Sena","year":"2020","unstructured":"Sena S et al (2020) Real-life data of direct anticoagulant use, bleeding risk and venous thromboembolism recurrence in chronic thromboembolic pulmonary hypertension patients: an observational retrospective study. Pulm Circ. https:\/\/doi.org\/10.1177\/2045894019873545","journal-title":"Pulm Circ"},{"issue":"3","key":"4257_CR28","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/2045893217717258","volume":"7","author":"T Jujo-Sanada","year":"2017","unstructured":"Jujo-Sanada T et al (2017) The anticoagulant effects of warfarin and the bleeding risk associated with its use in patients with chronic thromboembolic pulmonary hypertension at a specialist center in Japan: a retrospective cohort study. Pulm Circ 7(3):684\u2013691. https:\/\/doi.org\/10.1177\/2045893217717258","journal-title":"Pulm Circ"},{"issue":"6","key":"4257_CR29","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s00380-021-01799-x","volume":"36","author":"N Ikeda","year":"2021","unstructured":"Ikeda N, Amemiya K, Sato S, Iijima R, Hara H, Nakamura M (2021) Evolution of patients with chronic thromboembolic pulmonary hypertension treated by balloon pulmonary angioplasty, according to their anticoagulant regimens. Heart Vessels 36(6):910\u2013915. https:\/\/doi.org\/10.1007\/s00380-021-01799-x","journal-title":"Heart Vessels"},{"key":"4257_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.thromres.2023.07.002","volume":"229","author":"I Benzidia","year":"2023","unstructured":"Benzidia I et al (2023) Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension. Thromb Res 229:139\u2013145","journal-title":"Thromb Res"}],"updated-by":[{"DOI":"10.1007\/s11739-026-04317-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000}}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-04257-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-025-04257-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-025-04257-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:28:39Z","timestamp":1777958919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-025-04257-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4257"],"URL":"https:\/\/doi.org\/10.1007\/s11739-025-04257-y","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"19 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11739-026-04317-x","URL":"https:\/\/doi.org\/10.1007\/s11739-026-04317-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As a study-level analysis, no ethical approval was needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}